Overview

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Status:
Terminated

Trial end date:
2021-04-16

Target enrollment:

Participant gender:

Summary

This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie